Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Equal-Weight rating on Bristol-Myers Squibb (NYSE:BMY) and lowered the price target from $64 to $62.
July 28, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Equal-Weight rating on Bristol-Myers Squibb and lowered the price target from $64 to $62.
The lowering of the price target by Barclays from $64 to $62 indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Bristol-Myers Squibb's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100